JAZZ PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 105.1 USD | -0.94% |
|
-1.79% | -14.59% |
Presenter SpeechJason Gerberry (Analysts)The next company presenter at the BofA Annual Health ...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Companyâs lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
105.1
USD
Average target price
180.9
USD
Spread / Average Target
+72.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.59% | 6.62B | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +13.38% | 238B | |
| +6.98% | 204B | |
| -6.46% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Transcript : Jazz Pharmaceuticals plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10
